Print

pSivida Corp (PSDV) Reports Third Quarter Fiscal Year 2013 Results  
5/14/2013 8:13:52 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its third quarter ended March 31, 2013.

“We are very pleased that the FDA has accepted Alimera Sciences’ recently resubmitted New Drug Application for ILUVIEN® for chronic Diabetic Macular Edema (DME) and has set a PDUFA target date of October 17, 2013.

Help employers find you! Check out all the jobs and post your resume.

//-->